CELL & GENE THERAPY INSIGHTS

Vector bioprocessing – April 2022
Guest Editor:
Franz Gerner, Chief Technology Officer at Excision BioTherapeutics
Franz Gerner
Franz Gerner
Chief Technology Officer at Excision BioTherapeutics
Manufacturing of RCA-free adenoviral vectors

Manufacturing of RCA-free adenoviral vectors

N Scheer
Nico Scheer
Nico Scheer
Senior Consultant Business Development, CEVEC Pharmaceuticals
27 March 2022
Poster
Thinking big: the need for innovation in the production of lentivirus-based cell and gene therapies

Thinking big: the need for innovation in the production of lentivirus-based...

H Leinonen,
J Moscariello,
L Davies et al.
Hanna Leinonen
Hanna Leinonen
Senior Scientist, Kuopio Center for Gene and Cell Therapy
John Moscariello
John Moscariello
Executive Director, Viral Vector and Gene Editing Process Development, Bristol Myers Squibb
Lee Davies
Lee Davies
Director, Process Research & Development, Oxford Biomedica
Scott Cross
Scott Cross
Senior Principal, Dark Horse Consulting
Will Junker
Will Junker
Head of Vector Manufacturing Quality, Kite Pharma
23 April 2022
Expert Roundtable Video
Flexible & scalable solutions for AAV viral vector production using a templated platform

Flexible & scalable solutions for AAV viral vector production using...

E Fong
Eva Fong
Eva Fong
Principle Scientist, Virus and Gene Therapy Bioprocessing
20 April 2022
Innovator Insight
Clarification of recombinant adeno-associated virus (rAAV) & lentivirus from adherent culture

Clarification of recombinant adeno-associated virus (rAAV) & lentivirus...

R Chinnawar
N Marchand
Rajeshwar Chinnawar
Rajeshwar Chinnawar
at Pall
Nicholas Marchand
Nicholas Marchand
R&D Engineer at Pall Biotech
3 May 2022
Research Article
Vector bioprocessing spotlight
Vector bioprocessing spotlight
F Gerner
Future trends in viral vector process & product development
Future trends in viral vector process & product development
R Krishna
Considerations for demonstrating comparability of AAV processes
Considerations for demonstrating comparability of AAV processes
L Giersch
Accelerating cell & gene therapy workflows with next-generation analytical tools
Accelerating cell & gene therapy workflows with next-generation analytical tools
C Heger, PhD
View all

Raw and starting materials

1 March 2022

Preclinical and translational tools and strategies

16 February 2022

Tools of tomorrow

1 December 2021

Cell therapy bioprocessing and automation

1 November 2021

Gene therapy CMC and quality control

1 October 2021

New horizons for cell therapy: emerging platforms

1 October 2021
View all

  • Streamlined workflow solutions for cell and gene therapy analytics
    A Graband
    Annika Graband
    Annika Graband
    Product Manager, Cell Analysis Reagents at Miltenyi Biotec
    24 May 2022
    7
    Days
    7
    Hrs
    24
    Min
    Register

  • Improving T cell therapy manufacturing processes with automation and...
    E Zynda, PhD
    Evan Zynda, PhD
    Evan Zynda, PhD
    Staff Scientist, Cell Biology at Thermo Fisher Scientific
    26 May 2022
    9
    Days
    7
    Hrs
    24
    Min
    Register

  • Life on a chip - vascularized micro-tumor chips for mimicking clinical...
    C Hughes
    Chris Hughes
    Chris Hughes
    CSO at Aracari Biosciences
    8 Jun 2022
    22
    Days
    7
    Hrs
    24
    Min
    Register

  • Thinking translational: Things to consider in CAR T cell research workflows
    S Rösch, PhD
    Saskia Rösch, PhD
    Saskia Rösch, PhD
    Global Product Manager at Miltenyi Biotec
    22 Jun 2022
    36
    Days
    7
    Hrs
    24
    Min
    Register

  • Optimizing E. Coli cell growth performance with in-line, real-time OD600...
    T Buch
    R Shanbaky
    Tanja Buch
    Tanja Buch
    Technical Director at Biifactory Competence Center
    Ramsey Shanbaky
    Ramsey Shanbaky
    Bioprocess Applications Manger at C Technologies, Inc - a Repligen Company
    1 Jun 2022
    14
    Days
    15
    Hrs
    24
    Min
    Register

  • Accelerating cell therapy discovery & development with non-viral gene...
    D Hermanson
    X Patrinostro
    David Hermanson
    David Hermanson
    Senior Manager of R&D Applications, Cell and Gene Therapy at Bio-techne
    Xiaobai Patrinostro
    Xiaobai Patrinostro
    Manager of Genome Engineering Services, Cell and Gene Therapy at Bio-techne
    16 Jun 2022
    29
    Days
    15
    Hrs
    24
    Min
    Register

  • Monitoring of circulating CAR T cells
    A Graband,
    D Hünecke,
    D Bremm
    Annika Graband
    Annika Graband
    Product Manager, Cell Analysis Reagents at Miltenyi Biotec
    Dr. Sabine Hünecke
    Dr. Sabine Hünecke
    Head of Laboratory, Stem Cell Transplantation and Immunotherapy at University Hospital Frankfurt
    Dr. Melanie Bremm
    Dr. Melanie Bremm
    Deputy Head of Laboratory, Stem Cell Transplantation and Immunotherapy at University Hospital Frankfurt
    31 May 2022
    14
    Days
    7
    Hrs
    24
    Min
    Register

  • Applying an HPLC analytical platform for mRNA process monitoring
    N Pavlin
    Nejc Pavlin
    Nejc Pavlin
    Project Manager in Process Analytics Development at BIA Separations
    7 Jun 2022
    21
    Days
    7
    Hrs
    24
    Min
    Register
    • View all

  • Strategic partnering to enable cell therapy commercialization
    J Smith
    X de Mollerat du Jeu
    Jenessa Smith
    Jenessa Smith
    Associate Director of Process Development at ArsenalBio
    Xavier de Mollerat du Jeu
    Xavier de Mollerat du Jeu
    Senior Director, R&D, Cell and Gene Therapy at Thermo Fisher Scientific
    12 May 2022
    Watch now

  • From cells to purified capsids: How to develop a scalable rAAV process
    Å Hagner McWhirter
    Åsa Hagner McWhirter
    Åsa Hagner McWhirter
    Principal Scientist at Cytiva
    3 May 2022
    Watch now

  • Strategic supply chain design: flexibility and scalability considerations for...
    N Kulkarni, PhD
    G Linton, RA, AIA, LEED AP BD+C
    Niranjan Kulkarni, PhD
    Niranjan Kulkarni, PhD
    Senior Director, Consulting Services at CRB
    Grace Linton, RA, AIA, LEED AP BD+C
    Grace Linton, RA, AIA, LEED AP BD+C
    Director of Process Architecture at CRB
    28 April 2022
    Watch now

  • Manufacturing considerations for viral and non-viral platform selection
    V Slepushkin,
    A Noyes,
    A Hagerman et al.
    Vladimir Slepushkin
    Vladimir Slepushkin
    Global Head of Manufacturing at MedTherapy Biotech
    Aaron Noyes
    Aaron Noyes
    Vice President of Development at Codiak Biosciences
    Allison Hagerman
    Allison Hagerman
    Vice President, Product Development, Oncolytics Biotech
    Laurens Sierkstra
    Laurens Sierkstra
    Senior Director, Business Leader, Purification at Thermo Fisher Scientific
    10 May 2022
    Watch now

  • Process development excellence to de-risk and accelerate commercialization...
    B Baghbaderani
    Behnam Baghbaderani
    Behnam Baghbaderani
    Global Head, Process Development, Emerging Technologies at Lonza Pharma & Biotech
    5 May 2022
    Watch now

  • Removing technological barriers to efficient large-scale LV vector production
    R Lopez de Maturana,
    E Jackson-Holmes,
    M Neri et al.
    Rakel Lopez de Maturana
    Rakel Lopez de Maturana
    Qualified Person at VIVEbioTech
    Emily Jackson-Holmes
    Emily Jackson-Holmes
    Associate Product Manager at Thermo Fisher Scientific
    Margherita Neri
    Margherita Neri
    Vector Process Development Manager at AGC Biologics
    Steven G. Milian
    Steven G. Milian
    Senior Staff Scientist (Process Sciences), Science & Technology Pharma Services Viral Vector Services at Thermo Fisher Scientific
    Scott Jeffers
    Scott Jeffers
    Gene Therapy Research and Process Development Leader at Redpin Therapeutics
    26 April 2022
    Watch now
    • View all

    Channel content

    Considerations for demonstrating comparability of AAV processes

    Considerations for demonstrating comparability of AAV processes

    L Giersch
    Laura Giersch
    Laura Giersch
    Director of Technical Operations, Lysogene
    25 April 2022
    Viewpoint
    Accelerating cell & gene therapy workflows with next-generation analytical tools

    Accelerating cell & gene therapy workflows with next-generation analytical...

    C Heger, PhD
    Chris Heger, PhD
    Chris Heger, PhD
    Director, Applications Science, Analytical Solutions Division at Bio-techne
    24 April 2022
    Innovator Insight
    Key considerations when adopting Droplet Digital PCR for viral vector manufacture

    Key considerations when adopting Droplet Digital PCR for viral vector...

    M White
    Mark White
    Mark White
    Associate Director of Biopharma Product Marketing, Bio-Rad Laboratories
    24 February 2022
    FastFacts
    View all
    Fast chromatography of AAV – purification and analytics

    Fast chromatography of AAV – purification and analytics

    M Leskovec
    Maja Leskovec
    Maja Leskovec
    Head of Process Development Viruses, BIA Separations, a Sartorius company
    20 December 2021
    FastFacts
    Flexible & scalable solutions for AAV viral vector production using a templated platform

    Flexible & scalable solutions for AAV viral vector production using...

    E Fong
    Eva Fong
    Eva Fong
    Principle Scientist, Virus and Gene Therapy Bioprocessing
    20 April 2022
    Innovator Insight
    Rapid translation of a cellular therapeutic from research to clinic

    Rapid translation of a cellular therapeutic from research to clinic

    A Patel
    J Candiello
    Ashish Patel
    Ashish Patel
    Civil Engineer
    Joseph Candiello
    Joseph Candiello
    Senior Product Manager at RoosterBio Inc
    2 May 2022
    Webinar Digest
    View all
    Fast chromatography of AAV – purification and analytics

    Fast chromatography of AAV – purification and analytics

    M Leskovec
    Maja Leskovec
    Maja Leskovec
    Head of Process Development Viruses, BIA Separations, a Sartorius company
    20 December 2021
    FastFacts
    Rapid Quantitation of Viral Vectors with Simple Plex Microfluidic Immunoassays

    Rapid Quantitation of Viral Vectors with Simple Plex Microfluidic Immunoassays

    N Steere
    Nathan Steere
    Nathan Steere
    Commercial Product Manager, Bio-Techne
    20 December 2021
    FastFacts
    Flexible & scalable solutions for AAV viral vector production using a templated platform

    Flexible & scalable solutions for AAV viral vector production using...

    E Fong
    Eva Fong
    Eva Fong
    Principle Scientist, Virus and Gene Therapy Bioprocessing
    20 April 2022
    Innovator Insight
    View all
    Current global regulatory landscape for biodistribution & shedding assessment of rAAV gene therapies & recommendations of the IMI ARDAT consortium on future directions

    Current global regulatory landscape for biodistribution & shedding assessment...

    N Schmidt,
    J Giblin,
    T MacLachlan et al.
    Natalie Anne Schmidt
    Natalie Anne Schmidt
    Pfizer R & D Ltd., Global Regulatory Affairs, UK
    Jon Giblin
    Jon Giblin
    Asphalion SL, Barcelona, Spain
    Timothy K MacLachlan
    Timothy K MacLachlan
    Novartis Institutes for Biomedical Research, Cambridge, USA
    Shera Dandapat
    Shera Dandapat
    Janssen Research and Development, EMEA Regulatory Affairs, High Wycombe, UK
    Gabor Veres
    Gabor Veres
    Pharmacoidea Ltd., Szeged, Hungary
    Tatiana Anna Reimer
    Tatiana Anna Reimer
    Bayer AG, Cell & Gene Therapy Unit, Germany
    Martin Schulz
    Martin Schulz
    Pfizer Pharma GmbH, Berlin, Germany
    Eva Hatzmann
    Eva Hatzmann
    Sanofi, Global Regulatory Affairs, NL
    Andeleeb Dahy
    Andeleeb Dahy
    Astellas Pharma Europe B.V., Leiden, NL
    Gregory LaRosa
    Gregory LaRosa
    Pfizer Rare Disease Research Unit, Cambridge, MA, 01239, USA
    Mimoun Azzouz
    Mimoun Azzouz
    University of Sheffield, UK
    Christopher J Mann
    Christopher J Mann
    Asphalion SL, Barcelona, Spain
    24 April 2022
    Unproven stem cell-based interventions & harm to existing & future patients

    Unproven stem cell-based interventions & harm to existing & future patients

    F Naylor
    K Matthews
    Flora Naylor
    Flora Naylor
    Research Assistant Baker Institute for Public Policy, Rice University, Houston, TX USA
    Kirstin RW Matthews
    Kirstin RW Matthews
    Fellow for Science and Technology Policy, Baker Institute for Public Policy, Rice University, Houston, TX USA
    27 March 2022
    Editorial
    Standardization & analytical tool innovation in the cell & gene therapy field

    Standardization & analytical tool innovation in the cell & gene therapy...

    F Atouf
    Fouad Atouf
    Fouad Atouf
    Vice President of Global Biologics, United States Pharmacopeia
    3 March 2022
    Interview
    View all
    Key factors in cell cryopreservation and impact on manufacturability of cell and gene therapies

    Key factors in cell cryopreservation and impact on manufacturability...

    R Newman
    Robert Newman, PhD
    Robert Newman, PhD
    Chief Scientific Officer, FUJIFILM Irvine Scientific
    17 April 2022
    FastFacts
    Supply chain efficiency and sourcing for scaling your gene therapy operation

    Supply chain efficiency and sourcing for scaling your gene therapy operation

    C Martin
    D Young
    Céline Martin
    Céline Martin
    Senior Product Manager, Gene Therapy at Thermo Fisher Scientific
    Don Young
    Don Young
    Senior Global Product Manager, Single-Use Technologies at Thermo Fisher Scientific
    5 May 2022
    Poster
    A collaborative approach to cell & gene therapy supply chain management

    A collaborative approach to cell & gene therapy supply chain management

    A Johnson
    Anthony Johnson
    Anthony Johnson
    Head of Supply Chain & Warehouse Cell and Gene Therapy Catapult
    24 April 2022
    Interview
    View all
    Unleashing the full potential of cell therapy through RNA engineering

    Unleashing the full potential of cell therapy through RNA engineering

    M Kurtoglu
    Metin Kurtoglu
    Metin Kurtoglu
    Chief GMP Manufacturing and Chief Medical Officer at Cartesian Therapeutics
    10 May 2022
    Expert Insight
    Overcoming the immune-related shortfalls of AAV

    Overcoming the immune-related shortfalls of AAV

    G Winslow
    Genine Winslow
    Genine Winslow
    Founder & Chief Executive Officer at Chameleon Biosciences Inc
    9 May 2022
    Viewpoint
    Breaking new ground in the clinical application of CRISPR/Cas9

    Breaking new ground in the clinical application of CRISPR/Cas9

    L Sepp-Lorenzino
    Laura Sepp-Lorenzino
    Laura Sepp-Lorenzino
    Vice President, Head, Nucleic Acid Therapies at Vertex Pharmaceuticals Inc
    9 May 2022
    Interview
    View all
    Trends and considerations in cell and gene therapy M&A, partnering and IP

    Trends and considerations in cell and gene therapy M&A, partnering and...

    E Townsend
    Ewan Townsend
    Ewan Townsend
    Partner, Arnold & Porter
    10 May 2022
    Interview
    Early-stage investment in immuno oncology: riding the waves of hope & hype

    Early-stage investment in immuno oncology: riding the waves of hope...

    J Lesterhuis,
    H Mikkelsen,
    J Tobin et al.
    W Joost Lesterhuis
    W Joost Lesterhuis
    Brandon Capital Partners, Melbourne VIC, Australia Telethon Kids Institute, Nedlands WA, Australia School of Biomedical Sciences, University of Western Australia, Crawley WA, Australia
    Helga Mikkelsen
    Helga Mikkelsen
    Brandon Capital Partners, Melbourne VIC, Australia
    Jonathan Tobin
    Jonathan Tobin
    Brandon Capital Partners, Melbourne VIC, Australia
    Michael Bettess
    Michael Bettess
    Brandon Capital Partners, Melbourne VIC, Australia
    15 March 2022
    Viewpoint
    Immuno-oncology therapies: a looming mid-life crisis?

    Immuno-oncology therapies: a looming mid-life crisis?

    H Kim,
    D Liew,
    S Goodall
    Hansoo Kim
    Hansoo Kim
    Centre for Applied Health Economics, Griffith University, Australia
    Danny Liew
    Danny Liew
    Adelaide Medical School, The University of Adelaide, Australia
    Stephen Goodall
    Stephen Goodall
    Centre for Health Economic Research and Evaluation, University of Technology Sydney, Australia
    15 March 2022
    Commentary
    View all

    Reports

    Regulatory Insights April 2022

    Regulatory Insights April 2022
    13 April 2022

    FEATURING

    Current global regulatory landscape for biodistribution & shedding assessment of rAAV gene therapies & recommendations of the IMI ARDAT consortium on future directions
    N Schmidt,
    J Giblin,
    T MacLachlan et al.

    Unproven stem cell-based interventions & harm to existing & future patients
    F Naylor,
    K Matthews

    “This is not a sustainable model.”
    J DePinto,
    R Richards
    View all
    Clinical Trends March 2022

    Clinical Trends March 2022
    16 March 2022

    FEATURING

    Current global regulatory landscape for biodistribution & shedding assessment of rAAV gene therapies & recommendations of the IMI ARDAT consortium on future directions
    N Schmidt,
    J Giblin,
    T MacLachlan et al.

    Unproven stem cell-based interventions & harm to existing & future patients
    F Naylor,
    K Matthews

    “This is not a sustainable model.”
    J DePinto,
    R Richards
    View all
    Innovation Insights March 2022

    Innovation Insights March 2022
    16 March 2022

    FEATURING

    Current global regulatory landscape for biodistribution & shedding assessment of rAAV gene therapies & recommendations of the IMI ARDAT consortium on future directions
    N Schmidt,
    J Giblin,
    T MacLachlan et al.

    Unproven stem cell-based interventions & harm to existing & future patients
    F Naylor,
    K Matthews

    “This is not a sustainable model.”
    J DePinto,
    R Richards
    View all
    Business Insights February 2022

    Business Insights February 2022
    16 February 2022

    FEATURING

    Current global regulatory landscape for biodistribution & shedding assessment of rAAV gene therapies & recommendations of the IMI ARDAT consortium on future directions
    N Schmidt,
    J Giblin,
    T MacLachlan et al.

    Unproven stem cell-based interventions & harm to existing & future patients
    F Naylor,
    K Matthews

    “This is not a sustainable model.”
    J DePinto,
    R Richards
    View all
    Investor Insights October 2020

    Investor Insights October 2020
    1 October 2020

    FEATURING

    Current global regulatory landscape for biodistribution & shedding assessment of rAAV gene therapies & recommendations of the IMI ARDAT consortium on future directions
    N Schmidt,
    J Giblin,
    T MacLachlan et al.

    Unproven stem cell-based interventions & harm to existing & future patients
    F Naylor,
    K Matthews

    “This is not a sustainable model.”
    J DePinto,
    R Richards
    View all

    Latest content

    What does Plug-and-Play offer large-scale AAV manufacturing?
    M Neri
    C Wartel-Weill
    Margherita Neri
    Margherita Neri
    Vector process Development Manager at MolMed SpA
    Claire Wartel-Weill
    Claire Wartel-Weill
    Director, Quality & Compliance
    22 March 2022
    Watch now

    Flexible and scalable solutions for AAV viral vector production using a templated...
    E Fong
    Eva Fong
    Eva Fong
    Principal Scientist, Virus and Gene Therapy Bioprocessing at MilliporeSigma
    17 March 2022
    Watch now

    Automated GMP-compliant PSC banking in a closed system
    C Sheng, PhD
    R Krol, PhD
    Chao Sheng, PhD
    Chao Sheng, PhD
    Global Product Manager - Regenerative Medicine at Miltenyi Biotec
    Rafal Krol, PhD
    Rafal Krol, PhD
    Principal Investigator at CiRA Foundation
    15 March 2022
    Watch now

    Accelerate your cell and gene therapy workflows with next-generation analytical...
    C Heger, PhD
    Chris Heger, PhD
    Chris Heger, PhD
    Director, Applications Science, Analytical Solutions Division at Bio-techne
    8 March 2022
    Watch now

    Simplifying analytical development for viral vector production: robust and...
    S Kashi Ranganath
    Srinath Kashi Ranganath
    Srinath Kashi Ranganath
    Staff Scientist, Field Applications, Pharma Analytics Group at Thermo Fisher Scientific
    3 March 2022
    Watch now

    Rethink CAR T cell therapy with a scalable RNA lipid nanoparticle platform
    A Zhang, PhD
    R Geczy, PhD
    Angela Zhang, PhD
    Angela Zhang, PhD
    Senior Product Manager at Precision NanoSystems Inc
    Reka Geczy, PhD
    Reka Geczy, PhD
    Product Development Scientist at Precision NanoSystems Inc
    1 March 2022
    Watch now

    Introducing Lonza’s AAV suspension transient transfection platform to de-risk...
    S Sanyal
    Suparna Sanyal
    Suparna Sanyal
    Head of Viral Vectors Commercial Development at Lonza Pharma & Biotech
    24 February 2022
    Watch now

    Manufacturing of RCA-free adenoviral vectors
    N Scheer
    Nico Scheer
    Nico Scheer
    Senior Consultant Business Development at CEVEC Pharmaceuticals GmbH
    22 February 2022
    Watch now
    Manufacturing of RCA-free adenoviral vectors

    Manufacturing of RCA-free adenoviral vectors

    N Scheer
    Nico Scheer
    Nico Scheer
    Senior Consultant Business Development, CEVEC Pharmaceuticals
    27 March 2022
    Poster
    View all